Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Halts Hanmi BTK Inhibitor Trial For RA, Mulls Other Indications

Executive Summary

Hanmi Pharmaceutical shares fell sharply on the news Lilly has halted Phase II trials of the South  Korean firm’s BTK inhibitor for rheumatoid arthritis. But Hanmi says its license contract remains intact and that the two firms are discussing the potential development of the molecule for other indications.

You may also be interested in...



Rolontis Leads Hanmi’s Global Ambitions As ADVANCE Phase III Endpoint Met

Rolontis, a novel, long-acting granulocyte colony-stimulating factor (G-CSF) licensed out to Spectrum Pharmaceuticals, has become Hanmi Pharmaceuticals' first drug developed with its proprietary platform to approach the regulatory filings stage in global markets.

Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair

Hanmi shares have gone on a wild roller coaster ride as bad news came after good. A day after it announced a huge licensing agreement with Genentech, the South Korean firm unveiled that Boehringer Ingelheim had decided to return rights to olmutinib, the EGFR inhibitor it licensed from Hanmi last July.

Lilly Signs Major Collaboration With Hanmi For RA Drug

Lilly is building out its autoimmune pipeline through a licensing deal with Hanmi that could be worth $690 million to the Korean firm and is indicative of the growing attractiveness of innovation in the Asian country.

Topics

Related Companies

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel